A Randomized Phase II Trial of Deforolimus (AP23573; MK-8669) Compared to Progestin in Female Adult Patients With Advanced Endometrial Carcinoma Following One Line of Chemotherapy. [Ensayo en fase II randomizado de deforolimus (AP23573; MK-8669) comparado con progestinas en pacientes adultas con carcinoma endometrial avanzado que hayan recibido una línea de quimioterapia]

Trial Profile

A Randomized Phase II Trial of Deforolimus (AP23573; MK-8669) Compared to Progestin in Female Adult Patients With Advanced Endometrial Carcinoma Following One Line of Chemotherapy. [Ensayo en fase II randomizado de deforolimus (AP23573; MK-8669) comparado con progestinas en pacientes adultas con carcinoma endometrial avanzado que hayan recibido una línea de quimioterapia]

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Ridaforolimus (Primary) ; Antineoplastics; Medroxyprogesterone; Megestrol
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Sponsors ARIAD Pharmaceuticals; Merck & Co
  • Most Recent Events

    • 10 Aug 2012 Additional lead trial investigator identified as reported by UKCRN.
    • 09 Aug 2012 Actual end date Jul 2012 added as reported by ClinicalTrials.gov.
    • 21 Jul 2012 This trial has been recruiting in France, Italy, United Kingdom, discontinued in Germany and suspended in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top